Department of Endocrinology, University Hospital of Tübingen, 72076 Tübingen, Germany.
J Clin Endocrinol Metab. 2011 Sep;96(9):2665-9. doi: 10.1210/jc.2011-1166. Epub 2011 Jun 29.
Although pituitary adenomas are common, pituitary carcinoma is a very rare condition.
We report on a 48-yr-old male presenting with pituitary carcinoma with malignant growth from the beginning and a fulminant clinical course and give an overview of the previously reported cases, paying special attention to clinical and histological parameters that may predict the clinical course.
We performed a MEDLINE search for previously published cases of pituitary carcinoma and analyzed the clinical, laboratory, and radiological findings.
Ki-67 index and the number of metastatic diseases found on postmortem examination were significantly increased in patients with no treatment response compared to those with some treatment response (P = 0.03 and P = 0.02, respectively). In contrast, time to occurrence of metastatic disease and time to death were significantly shortened in patients with no treatment response (P = 0.01 and P = 0.02, respectively). No differences were found between the two groups for gender distribution, tumor size, mitotic activity assessed as the number of mitotic figures per 10 high-power fields, and number of locations of metastatic disease.
Frequently relapsing, invasive adenoma should raise a suspicion of a malignant disease. Clinically only the presence of metastases is a criterion of malignancy. A high Ki-67 index in the pituitary carcinoma and early manifestation of metastatic disease appear to predict rapid disease progression.
尽管垂体腺瘤很常见,但垂体癌是一种非常罕见的疾病。
我们报告了一例 48 岁男性垂体癌病例,其从一开始就具有恶性生长,并伴有暴发性临床病程,并对以前报道的病例进行了综述,特别关注可能预测临床病程的临床和组织学参数。
我们对以前发表的垂体癌病例进行了 MEDLINE 检索,并对临床、实验室和影像学发现进行了分析。
无治疗反应患者的 Ki-67 指数和尸检时发现的转移性疾病数量明显高于有治疗反应的患者(P=0.03 和 P=0.02)。相比之下,无治疗反应患者的转移性疾病发生时间和死亡时间明显缩短(P=0.01 和 P=0.02)。两组之间在性别分布、肿瘤大小、作为每 10 个高倍视野中核分裂数评估的有丝分裂活性以及转移性疾病的部位数量方面无差异。
频繁复发的侵袭性腺瘤应引起对恶性疾病的怀疑。临床上只有存在转移才是恶性的标准。垂体癌中高的 Ki-67 指数和转移性疾病的早期表现似乎预示着疾病的快速进展。